Diethylaminoethanol

Diethylaminoethanol

SCHEMBL537914

CCN(CC)CCO.CN(C)CCO

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.67
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CYP2D6 P10635 1/20 0.35
ALDH1A1 P00352 4/20 0.34
ALDH2 P05091 1/20 0.34
DNM1 Q05193 3/20 0.32
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA7 P43166 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylaminoethanol SCHEMBL9003859 0.92 MAPT (0.71) MAPTCYP1A2CYP2C9HPGDMAPK1
Diethylaminoethanol SCHEMBL4773320 0.91 MAPT (0.55) MAPTCYP1A2CYP2C9HPGDMAPK1
SCHEMBL9715505 0.90 MAPT (0.52) MAPTCYP1A2CYP2C9HPGDMAPK1
Diethylaminoethanol SCHEMBL10699915 0.88
Diethylaminoethanol SCHEMBL3114 0.88
SCHEMBL23117107 0.86 MAPT (0.55) MAPTCYP1A2CYP2C9HPGDMAPK1
Trolamine SCHEMBL15410677 0.85 MAPT (0.80) MAPTCYP1A2CYP2C9HPGDMAPK1
Trolamine SCHEMBL22749413 0.85 CYP1A2 (0.52) MAPTCYP1A2CYP2C9HPGDMAPK1
Diethylaminoethanol SCHEMBL20815437 0.85
Diethylaminoethanol SCHEMBL20293885 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369665-A1 POROUS FILM AND METHOD OF FORMING POROUS FILM FUJI XEROX CO., LTD. (JP) 2017-12-28 US claimed
JP-62190078-A None JP disclosed
US-10023528-B2 Branched 3-phenylpropionic acid derivatives and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-17 US disclosed
US-20170001947-A1 DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY SIRNA THERAPEUTICS, INC. (US) 2017-01-05 US disclosed
US-20160264515-A1 Branched 3-phenylpropionic acid derivatives and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-09-15 US disclosed
EP-2914610-A2 GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS GlycoMimetics, Inc. (US) 2015-09-09 EP disclosed
WO-2014070991-A2 E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2014-05-08 WO disclosed
EP-2414366-A1 SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE Novartis AG (CH) 2012-02-08 EP disclosed
WO-2010112520-A1 SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE NOVARTIS AG (CH) 2010-10-07 WO disclosed
US-7635701-B2 Pyrimidine derivatives and their use as CB2 modulators GLAXO GROUP LIMITED (GB) 2009-12-22 US disclosed
US-20060293354-A1 Pyrimidine derivatives and their use as CB2 modulators GLAXO GROUP LIMITED (GB) 2006-12-28 US disclosed
US-5773505-A Polymer emulsions with bimodal molecular-weight distribution ROEHM GMBH CHEMISCHE FABRIK (DE) 1998-06-30 US disclosed
US-4939191-A High strength cured cement article and process for manufacturing the same UBE INDUSTRIES, LTD. (JP) 1990-07-03 US disclosed
JP-S62190078-A PRODUCTION OF CHOLINE OXIDASE TOYOBO CO LTD 1987-08-20 JP disclosed
US-4582842-A Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor MERCK & CO., INC. (US) 1986-04-15 US disclosed
US-4297430-A WHEREIN DEVELOPMENT IS CARRIED OUT IN THE PRESENCE OF A CYCLIC IMIDE MITSUBISHI PAPER MILLS, LTD. (JP) 1981-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264515-A1 Branched 3-phenylpropionic acid derivatives and their use PC, FABP3, PCCA MAPT 3036/4885CYP1A2 1195/4885CYP2C9 1287/4885
US-20060293354-A1 Pyrimidine derivatives and their use as CB2 modulators CNR2, CNR1, P2RX3 MAPT 2894/4885CYP1A2 1273/4885CYP2C9 1187/4885
US-20170001947-A1 DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY NR1H4, LDLR, LIPA MAPT 3979/4885CYP1A2 4272/4885CYP2C9 4611/4885
US-10023528-B2 Branched 3-phenylpropionic acid derivatives and their use PC, FABP3, PCCA MAPT 3036/4885CYP1A2 1195/4885CYP2C9 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.